首页|Severe immune thrombocytopenia following COVID-19 vaccination (Moderna) and immune checkpoint inhibitor

Severe immune thrombocytopenia following COVID-19 vaccination (Moderna) and immune checkpoint inhibitor

扫码查看
原文链接
  • NSTL
  • Elsevier
? 2022 Elsevier Inc.Safe and effective prophylactic vaccines are urgently needed to contain the coronavirus disease 2019 (COVID-19) pandemic. However, several vaccination-related adverse effects have been reported. Here, we report a rare case of severe immune thrombocytopenia occurring 3 days after receiving the mRNA-1273 (Moderna) COVID-19 vaccine in an Asian woman with a history of refractory lung adenocarcinoma treated with durvalumab, an immune checkpoint inhibitor. Treatment with platelet transfusion (12 units) and oral prednisolone (1 mg/kg per day) significantly improved her hemoptysis with thrombocytopenia. To the best of our knowledge, this is the first case of ITP following Moderna inoculation among Asians. This study highlights a potential adverse effect of mRNA-based COVID-19 vaccines in cancer patients receiving immune checkpoint inhibitors.

COVID-19Immune checkpoint inhibitorsImmune thrombocytopeniaModerna vaccinemRNA-based vaccine

Chong K.-M.、Yang C.-Y.、Lin C.-C.、Lien W.-C.

展开 >

Department of Emergency Medicine National Taiwan University Hospital National Taiwan University

Division of Pulmonology Department of Internal Medicine National Taiwan University Hospital

Division of Hematology Department of Internal Medicine National Taiwan University Hospital National

2022

10.1016/j.ajem.2022.03.030

The American journal of emergency medicine

The American journal of emergency medicine

ISSN：0735-6757
年,卷(期)：2022.56
  • 3
  • 24